This record was last updated May 1, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center, randomized, double-blind, placebo-controlled study. Patients will be randomly assigned to either the peptide intervention group (with dose escalation at 15mg, 30mg, 60mg, and 75mg) or the placebo control group. After learning and training, participants will receive an injection of PMS-001. The efficacy and safety of the intervention will be assessed at 1 hour, 1 day, 3 days, and 1 week post-intervention. This study aims to evaluate the effects of PMS-001 on improving long-delay recall in patients with moderate to severe dementia, as well as its safety profile.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-18.